Maplight Therapeutics (NASDAQ:MPLT) Insider Sells $312,879.00 in Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) insider James Woodruff Lillie sold 11,095 shares of the company’s stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $28.20, for a total transaction of $312,879.00. Following the transaction, the insider owned 268,261 shares in the company, valued at approximately $7,564,960.20. This trade represents a 3.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Woodruff Lillie also recently made the following trade(s):

• On Wednesday, May 6th, James Woodruff Lillie sold 24,811 shares of Maplight Therapeutics stock. The stock was sold at an average price of $28.76, for a total transaction of $713,564.36.
• On Monday, May 4th, James Woodruff Lillie sold 15,801 shares of Maplight Therapeutics stock. The stock was sold at an average price of $27.96, for a total transaction of $441,795.96.

Maplight Therapeutics Trading Down 6.2%

Maplight Therapeutics stock opened at $27.40 on Friday. Maplight Therapeutics, Inc. has a 1 year low of $12.24 and a 1 year high of $33.28. The firm has a market cap of $1.17 billion and a P/E ratio of -0.69. The company’s 50-day simple moving average is $22.83.

Maplight Therapeutics (NASDAQ:MPLT) last released its earnings results on Thursday, March 26th. The company reported ($2.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($1.42). On average, research analysts expect that Maplight Therapeutics, Inc. will post -3.96 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. TD Cowen assumed coverage on shares of Maplight Therapeutics in a research report on Tuesday, April 7th. They set a “buy” rating on the stock. Needham & Company LLC assumed coverage on shares of Maplight Therapeutics in a research report on Wednesday, April 8th. They set a “buy” rating and a $37.00 target price on the stock. Canaccord Genuity Group assumed coverage on shares of Maplight Therapeutics in a research report on Thursday, March 19th. They set a “buy” rating and a $35.00 target price on the stock. Weiss Ratings assumed coverage on shares of Maplight Therapeutics in a research report on Thursday, January 22nd. They set a “sell (e)” rating on the stock. Finally, Wall Street Zen downgraded shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Maplight Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.43.

Maplight Therapeutics News Summary

Here are the key news stories impacting Maplight Therapeutics this week:

• Positive Sentiment: MapLight Therapeutics announced that management will participate in upcoming investor conferences, which can help keep the company visible to potential investors and may provide a near-term catalyst. MapLight Therapeutics to Participate in Upcoming Investor Conferences
• Positive Sentiment: Needham reiterated a Buy rating on MPLT, reinforcing Wall Street support for the stock and helping offset some of the recent negative sentiment. Needham Reaffirms Buy Rating
• Positive Sentiment: Recent analyst coverage elsewhere in the tape remained constructive, including Buy ratings and higher price targets, which supports the longer-term bullish case for MapLight Therapeutics. Analyst coverage summary
• Neutral Sentiment: The company’s recent earnings history remains mixed, with a prior quarterly loss wider than expected; this is still part of the backdrop but not the main driver of today’s move. MPLT earnings summary
• Negative Sentiment: Multiple insiders, including CEO Christopher Kroeger, CFO Vishwas Setia, and insiders James Woodruff Lillie and Erin Pennock Foff, sold shares over May 4–6. Although the sales were made under pre-arranged Rule 10b5-1 plans, the cluster of transactions can weigh on sentiment and suggest near-term selling pressure. CEO Form 4 filing
• Negative Sentiment: The repeated insider sales may be contributing to the stock’s decline today, as investors often view sustained insider selling as a cautionary signal even when it is pre-planned. Insider sale filing

Institutional Trading of Maplight Therapeutics

Hedge funds have recently modified their holdings of the company. Strs Ohio acquired a new stake in shares of Maplight Therapeutics in the 4th quarter valued at approximately $53,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Maplight Therapeutics in the 4th quarter valued at approximately $70,000. New York State Common Retirement Fund acquired a new stake in shares of Maplight Therapeutics in the 4th quarter valued at approximately $93,000. MetLife Investment Management LLC acquired a new stake in shares of Maplight Therapeutics in the 4th quarter valued at approximately $172,000. Finally, Walleye Capital LLC acquired a new stake in shares of Maplight Therapeutics in the 4th quarter valued at approximately $205,000.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.